> 数据图表如何了解医疗器械： 2025年前三季度销售费用率稳中有升2025-12-2医疗器械： 2025年前三季度销售费用率稳中有升 器械板块2025Q1-3销售费用（+5.3%）和销售费用率（+0.7pp）均有所提升。考虑到器械厂商25Q1-3营收短期承压，同时正在积极拓展新海外、基层以及线上等新市场，整体来看器械厂商加大了销售投入力度，销售费用率稳中有升。器械公司迈瑞医疗联影医疗鱼跃医疗三诺生物乐普医疗可孚医疗新华医疗昊海生科安图生物新产业南微医学华大智造大博医疗万孚生物开立医疗楚天科技迈克生物圣湘生物健帆生物欧普康视25Q1-337.415.212.39.38.28.26.36.05.95.85.25.15.04.84.84.34.34.23.83.7销售费用/亿元24Q1-336.613.99.38.49.77.16.45.95.55.24.76.34.74.74.64.54.43.45.13.4医药生物(申万)医疗器械(申万)2,2842752,337261数据来源：wind，西南证券整理yoy1.9%9.9%32.4%10.0%-15.7%14.6%-2.2%1.0%6.8%10.6%11.6%-19.4%7.8%2.7%4.4%-3.7%-1.8%23.4%-25.0%9.7%-2.3%5.3%25Q1-314.5%17.2%18.8%26.8%16.6%34.0%9.0%31.6%18.8%16.9%21.8%27.2%26.8%28.7%32.8%11.1%26.7%33.9%24.6%26.0%12.6%15.4%销售费用率24Q1-312.4%19.9%15.4%26.5%20.3%31.6%8.6%28.7%16.3%15.3%23.1%33.8%30.6%21.6%32.8%10.7%22.5%33.1%23.2%23.8%12.7%14.7%同比变化2.0pp-2.7pp3.4pp0.4pp-3.7pp2.4pp0.4pp3.0pp2.5pp1.6pp-1.3pp-6.6pp-3.7pp7.0pp0.0pp0.3pp4.3pp0.8pp1.4pp2.3pp-0.1pp0.7pp108西南证券健康医疗
